The trademark application KYSO was filed by Genmab A/S, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on February 22, 2022, and it was registered by office on June 1, 2022 without any oppositions.
It was designated 'Basic Application' for International Application 1670640 at the World Intellectual Property Organization (WIPO).
The application was filed in Danish (English was selected as the second language).
Change of name and address of the trademark registration was recorded on August 16, 2023.
Goods And Services
The mark was filed in class 1 with Chemical, biochemical, biological, and biotechnological preparations, especially antibodies, and bi- and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases and active chemical ingredients for use in the manufacture of pharmaceuticals..
The mark was filed in class 5 with Pharmaceutical and veterinary preparations, including pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to diseases.
The mark was filed in class 42 with following description of goods:
Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these
Chemical analysis
Computer programming, namely programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these.
The mark was filed in class 45 with Patent exploitation and licensing of intellectual property in the field of medicine.